Kyle LaHucik at Endpoints News speaks with our Managing Partner, James H. about current #IPO market trends. Only four biotechs from this year’s IPO class are trading above their debut pricings: CG Oncology, ArriVent BioPharma, Rapport Therapeutics and Contineum Therapeutics. Healy is on the boards of two of those: cancer drugmaker ArriVent, which is in late-stage testing with a drug out of a China-based partner; and neuroscience startup Rapport, which spun out of Johnson & Johnson and quickly raised successive megarounds before landing on the Nasdaq. Read the article here: https://lnkd.in/gGbteK4T
Sofinnova Investments
Investment Management
Menlo Park, CA 8,157 followers
Innovation for Life
About us
Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We invest in both private and public equity companies. Sofinnova actively partners with entrepreneurs across all stages of company formation, we are long-term investors with extensive scientific expertise, vast industry knowledge, and a track record of helping forge the path from drug development and navigating the regulatory process to company building and IPO or M&A. Founded in 1976, Sofinnova has a long legacy of building what we believe are great companies in both the U.S. and Europe with approximately $3.3B in assets under management and committed capital as of 6/30/2024.
- Website
-
http://www.sofinnova.com
External link for Sofinnova Investments
- Industry
- Investment Management
- Company size
- 11-50 employees
- Headquarters
- Menlo Park, CA
- Type
- Partnership
- Founded
- 1976
- Specialties
- Venture Capital, Lifescience, Biotech, Hedge Fund, Innovation, Financial Services, and Investment Management
Locations
-
Primary
3000 Sand Hill Rd 4-250
Suite 150
Menlo Park, CA 94025, US
Employees at Sofinnova Investments
Updates
-
We are excited to welcome Dr. Maha Radhakrishnan as Executive Partner to the Sofinnova Investments team! Dr. Radhakrishnan brings more than two decades of expertise in the field of cardiology and other therapeutic areas, with long-standing and deep experience in developing therapies and programs dedicated to addressing high unmet medical needs. We believe she will add incredible value to our team and our portfolio companies by helping select and support new clinical-stage investment opportunities. Welcome Dr. Radhakrishnan! Read the full press release here: https://lnkd.in/erfCpmWH
-
We’re excited to share news of our latest #investment📢: Marea Therapeutics, a clinical-stage biotechnology company developing next-generation medicines for cardiometabolic diseases, today announced launching with $190 million in combined Series A and B financings (Series B led by Sofinnova Investments ). General Partner, Maha Katabi, PhD, CFA will join the Board of Directors. We are thrilled to partner with such a distinguished team and look forward to supporting Marea’s mission to develop transformative therapies for patients with cardiometabolic disease. #innovation #cardiometabolic #biotech #funding Read the full press release here: https://lnkd.in/eM5MrHtD
Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases
businesswire.com
-
Sofinnova Portfolio News: 🎉 Congratulations to Abraham (Abe) Ceesay, Troy Ignelzi, and the entire team at Rapport Therapeutics on such an incredible milestone!
We are so excited today to announce the pricing of our Initial Public Offering (IPO). We believe this important milestone will position us well as we look to further invest in our pipeline and advance our vision of transforming the lives of patients with CNS disorders. We expect shares of Rapport to start trading on Nasdaq Exchange tomorrow under the ticker symbol “RAPP”. Today would not have been possible without the relentless determination and commitment of our incredible team of Rapptors. Thank you! https://bit.ly/3yYDQZ0 #IPO #Innovation #BostonBiotech #Biotech
Rapport Therapeutics Announces Pricing of Initial Public Offering
globenewswire.com
-
Sofinnova Investments is excited to be on-site at #BIO2024 this week in San Diego! 🌍🔬 Join us as Jakob Dupont, MD MA, Executive Partner, shares his expertise on two panels: 📆 AI in Oncology: Wednesday, June 5th at 3pm. Discover how artificial intelligence is revolutionizing cancer treatment and research. 📆 Inside the VC Playbook: Thursday, June 6th at 10:15am. Gain valuable insights into venture capital funding and overcoming obstacles in challenging markets for success. We look forward to connecting! #AIinOncology #VCFunding #HealthcareInnovation #BIO2024
-
#ICYMI: Our Executive Partner, Jakob Dupont, MD MA was a panelist at #LABEST2024 Main-Event Day on Thursday, May 23rd, at the UCLA Luskin Center. It was an honor to join such a distinguished panel of experts in venture capital for a discussion on "The Latest Trends in Venture Capital Investing." Moderated by Josh Green, Chairman Emeritus of the National Venture Capital Association, the panel also featured insights from: 🌟 Mira Chaurushiya, Managing Director, Westlake Village Biopartners 🌟 Sahil Chopra, Principal, Vertex Ventures HC 🌟 Stacy Feld, Regional Head, West North America, J&J Innovation The discussion centered around the current landscape of venture capital, exploring emerging trends and shared perspectives on future opportunities in the industry. A big thank you to everyone who attended and contributed to the vibrant discussion. Looking forward to seeing how these trends will shape the future of venture capital! #VentureCapital #Investing #LABEST #UCLA #Innovation
-
🎉A huge thank you to Cesar Perez-Ramirez, PhD, Eric Hsu, Erin Huiting, Heraclitos Lefcochilos-Fogelquist, and Urjeet Khanwalkar for your time and #dedication while working with us at Sofinnova Investments! 💫It’s been an incredible 11 months and we are impressed by everyone’s level of engagement. We look forward to seeing you continue to thrive in your future endeavors! #thankyou #fellowshipprogram #innovation
-
Join our team and make an impact in funding tomorrow’s cures. #innovation
-
We’re excited to co-lead a $100M Series A in Seaport Therapeutics alongside ARCH Venture Partners, Third Rock Ventures, and Seaport founder PureTech Health. 🚀🚀🚀 Seaport is advancing a clinical-stage pipeline of novel #neuropsychiatric medicines powered by its proprietary Glyph™ Technology Platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms. “Seaport has the potential to meaningfully change the lives of patients with neuropsychiatric disorders,” said James H., M.D., Ph.D., Managing Partner at Sofinnova Investments. “We’ve had the pleasure of knowing Steven Paul and Daphne Zohar for a number of years, as one of the investors in Karuna, and we believe this team has the unique expertise to help solve the challenges of treating serious mental health conditions. I am eager to support Seaport as an investor and board member as the team continues to advance its clinical-stage pipeline of novel therapeutics.” Read the press release: https://lnkd.in/gG9qvmv7
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
businesswire.com
-
🎉 Maha Katabi, PhD, CFA featured in the latest National Venture Capital Association #MemberSpotlight highlighting Sofinnova Investments passion for: ☑ Funding healthcare #innovation ☑ Commitment to scientific #expertise ☑ Focus on patient #impact ☑ Collaboration within the #ventureecosystem 💫 "At Sofinnova, we are funding scientific and medical innovation to develop tomorrow’s cures. Value creation driven by innovation across disease spectrums remains a priority as we seek to improve the lives of patients through science."
💡 In our latest #MemberSpotlight, we had the privilege of speaking with Maha Katabi, PhD, CFA, General Partner at Sofinnova Investments . Sofinnova is dedicated to funding groundbreaking therapies that transform patient lives, with $3.7B in assets under management and a portfolio boasting 27 FDA approved drugs. Their approach is therapeutic-agnostic, allowing them to invest across various areas, targeting breakthrough treatments addressing unmet medical needs. With a focus on innovation and patient impact, Sofinnova is poised to continue leading the charge in healthcare investment in 2024 and beyond. 🔗 Learn more about their commitment to innovation and patient impact: https://lnkd.in/dkPDWPzX #HealthcareInvestment #Innovation #BioTech #VentureCapital